Brief: Iveric Bio Reports Fourth Quarter And Full Year 2021 Operational Highlights And Financial Results

IVERIC bio

24/02/2022 12:06

Feb 24 (Reuters) - Iveric Bio Inc  ISEE.O :
    * IVERIC BIO REPORTS FOURTH QUARTER AND FULL YEAR 2021
OPERATIONAL
HIGHLIGHTS AND FINANCIAL RESULTS
    * Q4 LOSS PER SHARE $0.29
    * AS OF DECEMBER 31, 2021, COMPANY HAD APPROXIMATELY $381.7
MILLION IN CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES
    * ESTIMATES ITS YEAR-END 2022 CASH, CASH EQUIVALENTS AND
MARKETABLE SECURITIES WILL RANGE BETWEEN $215 MILLION AND $225
MILLION
    * IVERIC BIO - ESTIMATES AVAILABLE CASH, SECURITIES TO BE
SUFFICIENT TO FUND PLANNED CAPEX NEED, OPERATING EXPENSES
THROUGH AT LEAST MID-2024
    * Q4 EARNINGS PER SHARE VIEW $-0.25 -- REFINITIV IBES DATA
    * ZIMURA GATHER2 TOPLINE DATA EXPECTED IN SECOND HALF OF
2022
    * ZIMURA PHASE 3 CLINICAL TRIAL FOR INTERMEDIATE AMD TO
INITIATE
IN SECOND HALF OF 2022

Source text for Eikon:  ID:nBwjry2Ha 
Further company coverage:  ISEE.O 

 ((Reuters.Briefs@thomsonreuters.com;))